GlassScriptPhysician profile
Jeffry A Ross
NPI 1588864284
$7,232.35
in general payments reported to CMS, 2019-2025
17 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $1,076 · 2021: $1,212 · 2022: $1,048 · 2023: $681 · 2024: $1,095 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,793 · Entertainment: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.89 |
| Entertainment | $137.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,866.62 | 2019-2025 | Total30, Precision7 |
| Allergan, INC. | $1,116.89 | 2019-2022 | |
| Abbvie INC. | $906.97 | 2022-2025 | Alphagan P, Lumigan |
| Johnson & Johnson Vision Care, INC. | $804.04 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $553.14 | 2020-2025 | Cequa |
| Oyster Point Pharma, INC. | $525.34 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $451.81 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $202.64 | 2019 | |
| Harrow Eye, LLC | $173.67 | 2025 | Vevye |
| Coopervision INC. | $159.52 | 2019-2023 | Myday Contact Lens |
| Optos, INC. | $158.23 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Surgical Vision, INC. | $114.66 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.49 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.99 | 2020-2023 | |
| Lombart Brothers, INC. | $26.82 | 2024 | Opd-III |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $24.64 | 2023 | Infuse |
| Kala Pharmaceuticals, INC. | $19.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffry Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.